Halozyme to Present at Upcoming Investor Conferences

Rhea-AI Summary

Halozyme CEO to present at investor conferences: Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, Morgan Stanley Global Healthcare Conference, and Baird Global Healthcare Conference.

SAN DIEGO, Aug. 31, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences. 

Details on the presentations are as follow:

Event:				2023 Wells Fargo Healthcare Conference
Format:				Fireside Chat and 1x1 Meetings
Presentation Date:				Thursday, September 7, 2023
Presentation Time:				8:00 a.m. ET / 5:00 a.m. PT
Location:				Boston, MA
Event:				H.C. Wainwright 25th Annual Global Investment Conference
Format:				Fireside Chat and 1x1 Meetings
Presentation Date:				Monday, September 11, 2023
Presentation Time:				9:30 a.m. ET / 6:30 a.m. PT
Location:				New York, NY
Event:				Morgan Stanley 21st Annual Global Healthcare Conference
Format:				Fireside Chat and 1x1 Meetings
Presentation Date:				Tuesday, September 12, 2023
Presentation Time:				10:50 a.m. ET / 7:50 a.m. PT
Location:				New York, NY
Event:				Baird 2023 Global Healthcare Conference
Format:				Fireside Chat and 1x1 Meetings
Presentation Date:				Wednesday, September 13, 2023
Presentation Time:				1:25 p.m. ET / 10:25 a.m. PT
Location:				New York, NY

A live audio webcast of the Wells Fargo, H.C. Wainwright and Morgan Stanley presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 700,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED®, TLANDO® and NOCDURNA® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com

Dawn Schottlandt 
Argot Partners
212-600-1902
Halozyme@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-present-at-upcoming-investor-conferences-301914448.html

SOURCE Halozyme Therapeutics, Inc.